Daily Archives: 25 March, 2021

Mar. 2021 | Mainstay Medical Announces Commercial Launch of ReActiv8® in Australia

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…

Feb. 2021 | Poxel Announces Completion of Arbitration with Merck Serono

Poxel Announces Completion of Arbitration with Merck Serono Poxel SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced the completion of its arbitration with Merck Serono.

Feb. 2021 | Mainstay Medical Announces US$108 Million Equity Financing Transaction

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…

Feb. 2021 | Pharnext Announces Financing of €11 Million Through a Capital Raise Subscribed by Existing Shareholders and a Convertible Bonds Issued to European Investors; European Investors Also Provide Indication of Interest for an Additional Amount of up to €25 Million in Convertible Bonds

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…

Jan. 2021 | Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…

Jan. 2021 | Poxel Regains Imeglimin Rights From Metavant

Poxel Regains Imeglimin Rights From Metavant Poxel SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that, as part of the previously communicated decision by Metavant not to advance Imeglimin into a Phase 3 program for strategic reasons, its partnership…

Nov. 2020 | IPF Partners announces Final Close of its second Healthcare Growth Debt Fund at c. €187m, well over the initial €140m target

Mauna Kea Technologies (Euronext: MKEA) inventor of Cellvizio®, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/ nCLE ) platform…